Biotechnology Advances in Cancer and Sickle Cell Treatments
Thursday, 26 September 2024, 12:24
Biotechnology plays a pivotal role in addressing cancer and sickle cell diseases. Genentech's recent shutdown of its cancer immunology team and Pfizer's withdrawal from sickle cell treatment highlight significant shifts in the medical landscape. Additionally, new developments in schizophrenia medications reveal ongoing innovations in biotechnology.
These changes pose new opportunities and challenges for the medical community.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.